Illumina Inc. (ILMN)

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...

Seasoned healthcare CFO with senior experience in capital markets and financial operations across private and publicly traded companies to lead BioStem's financial team POMPANO BEACH, FL, August 14, 2...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for thei...

Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Illumina exceeded Q2FY25 expectations and raised FY25 guidance, driven by resilient Chinese operations and strong clinical market growth, especially in oncology. The company is expanding into proteomi...

Illumina (ILMN) Q2 EPS Jumps 9%

Illumina, Inc. ILMN reported better-than-expected earnings for the second quarter on Thursday.

Illumina, Inc. (NASDAQ:ILMN ) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Ankur Dhingra - Chief Financial Officer Brian Blanchett - VP of Finance & Treasurer and Int...

Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street ...